New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
15:12 EDTOREXOrexigen Therapeutics volatility elevated into PDUFA
Orexigen Therapeutics June call option implied volatility is at 154, July is at 109, October is at 84; compared to its 26-week average of 82 according to Track Data, suggesting large movement into the PDUFA goal date of June 11 for Contrave.
News For OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
09:17 EDTOREXOn The Fly: Pre-market Movers
Subscribe for More Information
08:10 EDTOREXOrexigen announces allowance of new U.S. patent for Contrave
Orexigen Therapeutics announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for U.S. Patent Application No. 11/757,773, which covers use of Orexigen's sustained release formulation of naltrexone, which was designed to improve drug tolerability for Contrave in a method for treating obesity. The patent is expected to expire in March of 2028. Orexigen expects the patent to be listed in the Orange Book maintained by the FDA.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use